Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Other Non-Current Liabilities (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Other Non-Current Liabilities for 10 consecutive years, with $16.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Liabilities rose 302.49% year-over-year to $16.6 million, compared with a TTM value of $16.6 million through Sep 2025, up 302.49%, and an annual FY2024 reading of $4.2 million, down 18.28% over the prior year.
  • Other Non-Current Liabilities was $16.6 million for Q3 2025 at Kiora Pharmaceuticals, roughly flat from $16.6 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $18.8 million in Q1 2023 and bottomed at $3.0 million in Q1 2022.
  • Average Other Non-Current Liabilities over 5 years is $8.1 million, with a median of $5.2 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities surged 528.98% in 2023, then crashed 78.02% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $3.0 million in 2021, then increased by 9.53% to $3.3 million in 2022, then soared by 53.58% to $5.1 million in 2023, then fell by 18.28% to $4.2 million in 2024, then surged by 296.88% to $16.6 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for KPRX at $16.6 million in Q3 2025, $16.6 million in Q2 2025, and $4.5 million in Q1 2025.